CL
TVTX icon

CSS LLC’s Travere Therapeutics TVTX Stock Holding History

CSS LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,000
Closed -$121K – 1168
2022
Q2 		$121K Buy
+5,000
New +$126K ﹤0.01% 867
2022
Q1 		– Sell
-12,400
Closed -$385K – 1323
2021
Q4 		$385K Hold
12,400
– – 0.01% 737
2021
Q3 		$301K Buy
12,400
+300
+2% +$5.51K 0.01% 781
2021
Q2 		$177K Buy
12,100
+3,000
+33% +$59.2K 0.01% 864
2021
Q1 		$227K Buy
+9,100
New +$251K 0.01% 743

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSS LLC's TVTX Position: Q1 2026 in Review

CSS LLC opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 7,470 shares worth $222K. The stake represents 0.01% of the portfolio and ranks #730 among its holdings. This is a return to the name: CSS LLC previously reported a position in TVTX as recently as Q3 2022.

CSS LLC first reported a position in TVTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $704K in Q2 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • CSS LLC held 7,470 shares of Travere Therapeutics worth $222K as of Q1 2026.
  • Travere Therapeutics was a new CSS LLC position in Q1 2026.
  • Travere Therapeutics made up 0.01% of CSS LLC's portfolio in Q1 2026, its #730 holding.
  • CSS LLC first reported a position in Travere Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • CSS LLC's Travere Therapeutics position peaked at $704K in Q2 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.